115 related articles for article (PubMed ID: 22015635)
21. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
22. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
[TBL] [Abstract][Full Text] [Related]
23. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
24. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
25. DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by 32P-postlabelling and immunoassay.
Gyorffy E; Anna L; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Poirier MC; Schoket B
Carcinogenesis; 2004 Jul; 25(7):1201-9. PubMed ID: 15001535
[TBL] [Abstract][Full Text] [Related]
26. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
[TBL] [Abstract][Full Text] [Related]
28. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
29. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
30. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
31. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
Reed E; Parker RJ; Gill I; Bicher A; Dabholkar M; Vionnet JA; Bostick-Bruton F; Tarone R; Muggia FM
Cancer Res; 1993 Aug; 53(16):3694-9. PubMed ID: 8339278
[TBL] [Abstract][Full Text] [Related]
32. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
35. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
36. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
Hah SS; Stivers KM; de Vere White RW; Henderson PT
Chem Res Toxicol; 2006 May; 19(5):622-6. PubMed ID: 16696564
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
39. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Bartelink IH; Prideaux B; Krings G; Wilmes L; Lee PRE; Bo P; Hann B; Coppé JP; Heditsian D; Swigart-Brown L; Jones EF; Magnitsky S; Keizer RJ; de Vries N; Rosing H; Pawlowska N; Thomas S; Dhawan M; Aggarwal R; Munster PN; Esserman LJ; Ruan W; Wu AHB; Yee D; Dartois V; Savic RM; Wolf DM; van 't Veer L
Breast Cancer Res; 2017 Sep; 19(1):107. PubMed ID: 28893315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]